GenSight Biologics S.A. announced that Thomas Gidoin, Chief Financial Officer since 2015, has resigned, effective January 26, 2024. An interim CFO was appointed until a permanent replacement is recruited.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.311 EUR | +2.13% |
|
-3.42% | -32.39% |
Jun. 03 | Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors | CI |
Jun. 03 | Gensight Biologics S.A. Appoints Ivan Tortet as Chief Financial Officer | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.39% | 34.83M | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- SIGHT Stock
- News GenSight Biologics S.A.
- Gensight Biologics S.A. Announces CFO Changes